The insulin resistance syndrome: Impact on lipoprotein metebolism and atherothrombosis

Journal of Cardiovascular Risk

Volumn 7, Issue 5, 2000, Pages 325-331

  Ginsberg, H N ^a   Huang, L S ^a  

^a New York Presbyterian Columbia University Medical Center   (United States)

Author keywords

Atherosclerotic cardiovascular disease; Diabetes mellitus; Dyslipidemia; HDL cholesterol; Insulin resistance; LDL cholesterol; Metabolic syndrome; Plasminogen activator inhibitor 1; Syndrome X; VLDL triglycerides

Indexed keywords

CHOLESTEROL ESTER; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN;

ARTERY THROMBOSIS; ATHEROSCLEROSIS; DYSLIPIDEMIA; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LIPOPROTEIN METABOLISM; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; REVIEW;

CORONARY ARTERIOSCLEROSIS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INCIDENCE; INSULIN RESISTANCE; LIPOPROTEINS; MALE; PROGNOSIS; RISK ASSESSMENT;

EID: 84910110212     PISSN: 13506277     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (110)

1. Prevalence and incidence of insulin-dependent diabetes
2. Mortality in non-insulin-dependent diabetes
3. Report of the National Cholesterol Education Program Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults
4. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II)
5. Role of cardiovascular risk factors in prevention and treatment of macrovascular disease in diabetes
6. Diabetes and heart disease
7. Role of insulin in regulation of lipoprotein metabolism in diabetes
8. Role of insulin resistance in human disease
9. Increased plasma PAI-1 levels: A possible link between insulin resistance and atherothrombosis
10. Insulin resistance in hyperglyceridemia
11. Role of insulin in endogenous hypertriglyceridemia
12. Reappraisal of the role of insulin in hypertriglyceridemia
13. Effects of weight reduction on obesity. Studies of lipid and carbohydrate metabolism in normal and hyperlipoproteinemic subjects
14. Intercorrelations among high density lipoproteins, obesity, and triglycerides in a normal population
15. Differences in insulin suppression of free fatty acid levels by gender and glucose tolerance status. Relation to plasma triglyceride and apolipoprotein B concentrations. Insulin Resistance Atherosclerosis Study (IRAS) Investigators
16. Relationships between insulin resistance and lipoproteins in nondiabetic African Americans, Hispanics, and Non-Hispanic Whites: The Insulin Resistance Atherosclerosis Study
17. Metabolism of very low density lipoproteins in hyperlipidemia: Studies of apolipoprotein B kinetics in man
18. Integrated regulation of very-low-density lipoprotein triglyceride and apolipoprotein-B kinetics in non-insulin-dependent diabetes mellitus
19. Effect of caloric restriction on very low density lipoprotein triglyceride metabolism in subjects with diabetes mellitus
20. Very-low density lipoprotein triglyceride metabolism in non- insulin-dependent diabetes mellitus: Relationship to plasma insulin and free fatty acids
21. Interrelationship among insulin's antilipolytic and glucoregulatory effects and plasma triglycerides in nondiabetic and diabetic patients with endogenous hypertriglyceridemia
22. Impaired fatty acid metabolism in familial combined hyperlipidemia. A mechanism associating hepatic apolipoprotein B overproduction and insulin resistance
23. Fatty acids and insulin resistance
24. Effects of fat on glucose uptake and utilization in patients with non-insulin-dependent diabetes
25. Mechanisms of fatty acid-induced inhibition of glucose uptake
26. Lipoprotein physiology in nondiabetic and diabetes states
27. Effect of insulin therapy on metabolic fate of apolipoprotein B-containing lipoproteins in NIDDM
28. Effects of acute hyperinsulinemia on VLDL triglyceride and VLDL apoB production in normal weight and obese individuals
29. Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans
30. Metabolic basis of hypotriglyceridemic effects of insulin in normal men
31. Effects of insulin and acipimox on VLDL1 and VLDL2 apolipoprotein B production in normal subjects
32. Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM
33. Lipoprotein lipase and hepatic lipase
34. Lipoprotein lipase in diabetes
35. Reversible abnormalities in postheparin lipolytic activity during the late phase of release in diabetes mellitus (postheparin lipolytic activity in diabetes)
36. Metabolism of cholesterol and triglycerides in nonketotic diabetes mellitus
37. An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3' untranslated region polymorphisms
38. Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia
39. Transcriptional regulation of the apoC-III gene by insulin in diabetic mice: Correlation with changes in plasma triglyceride levels
40. Very low density lipoprotein overproduction in genetic forms of hypertriglyceridemia
41. Metabolic basis of hyperapobetalipoproteinemia: Turnover of apolipoprotein B in low density lipoprotein and its precursors and subfractions compared with normal and familial hypercholesterolemia
42. Quantitative studies of very low density lipoprotein: Conversion to low density lipoprotein in normal controls and primary hyperlipidaemic states and the role of direct secretion of low density lipoprotein in heterozygous familial hypercholesterolaemia
43. Integrated regulation for very low density lipoprotein triglyceride and apolipoprotein-B kinetics in man: Normolipidemic subjects, familial hypertriglyceridemia and familial combined hyperlipidemia
44. Low density lipoprotein metabolism in familial combined hyperlipdemia: Mechanism of the multiple lipoprotein phenotypic expression
45. Influence of obesity on the metabolism of apolipoprotein B in humans
46. Transport kinetics of plasma free fatty acid, very low density lipoprotein triglycerides and apoprotein in patients with endogenous hypertriglycerideaemia
47. Very low density lipoprotein metabolism in lipoatrophic diabetes
48. Integrated study of low density lipoprotein metabolism and very low density lipoprotein in non-insulin-dependent diabetes
49. The effects of NIDDM on very-low-density lipoprotein triglyceride and apolipoprotein B metabolism: Studies before and after sulfonylurea therapy
50. Apolipoprotein B: Structure, biosynthesis and role in the lipoprotein assembly process
51. Regulation of hepatic secretion of apolipoprotein B-containing lipoproteins: Information obtained from cultured liver cells
52. The apolipoprotein B gene is constitutively expressed in HepG2 cells: Regulation of secretion by oleic acid, albumin, and insulin, and measurement of the mRNA half-life
53. Oleic acid stimulation of apolipoprotein B secretion from HepG2 and Caco-2 cells occurs post-transcriptionally
54. Effects of oleate and insulin on the production rates and cellular mRNA concentrations of apolipoproteins in HepG2 cells
55. ApoB-100 has a pentapartite structure composed of three amphipathic alpha-helical domains alternating with two amphipathic beta-strand domains. Detection by the computer program LOCATE
56. Structure of apolipoprotein B-100 of human low density lipoproteins
57. Polypeptide translocation: A pretty picture is worth a thousand words
58. The assembly and secretion of ApoB 100 containing lipoproteins in Hep G2 cells. Evidence for different sites for protein synthesis and lipoprotein assembly
59. Biosynthesis of lipoprotein: Location of nascent apoAl and apoB in the rough endoplasmic reticulum of chicken hepatocytes
60. Apolipoprotein B is both integrated into and translocated across the endoplasmic reticulum membrane. Evidence for two functionally distinct pools
61. Studies of the sites of intracellular degradation of apolipoprotein B in Hep G2 cells
62. Ubiquitin-proteasome pathway mediates intracellular degradation of apolipoprotein B
63. The degradation of apolipoprotein B100 is mediated by the ubiquitin-proteasome pathway and involves heat shock protein 70
64. Insulin modulation of hepatic synthesis and secretion of apolipoprotein B by rat hepatocytes
65. Insulin regulation of triacylglycerol-rich lipoprotein synthesis and secretion
66. Insulin-mediated inhibition of apolipoprotein B secretion requires an intracellular trafficking event and phosphatidylinositol 3-kinase activation: Studies with brefeldin A and wortmannin in primary cultures of rat hepatocytes
67. Impaired hepatic apolipoprotein B and E translation in streptozotocin diabetic rats
68. Restoration in vitro of normal rates of very-low-density lipoprotein triacylglycerol and apoprotein B secretion in hepatocyte cultures from diabetic rats
69. Reduced plasma high density lipoprotein-cholesterol concentrations need not increase when hyperglycemia is controlled with insulin in noninsulin-dependent diabetes mellitus
70. Diabetes blood lipids and the role of obesity in coronary heart disease risk for women. The Framingham study
71. Serum lipids and lipoproteins in newly diagnosed non-insulin-dependent (type II) diabetic patients with special reference to factors influencing HDL-cholesterol and triglyceride levels
72. Insulin resistance is associated with lipid and lipoprotein abnormalities in subjects with varying degrees of glucose tolerance
73. Plasma lipid transfer proteins
74. Accelerated cholesteryl ester transfer in noninsulin-dependent diabetes mellitus
75. Increased plasma and renal clearance of an exchangeable pool of apolipoprotein A-I in subjects with low levels of high density lipoprotein cholesterol
76. Triglyceride enrichment of HDL enhances in vivo metabolic clearance of HDL apo A-1 in healthy men
77. Analysis of particle size and lipid composition as determinants of the metabolic clearance of human high density lipoproteins in a rabbit model
78. Increased esterification of cholesterol and transfer of cholesteryl ester to apo B-containing lipoproteins in type 2 diabetes: Relationship to serum lipoproteins A-I and A-II
79. Fasting and posptrandial determinants for the occurrence of small dense LDL species in non-insulin-dependent diabetic patients with and without hypertriglyceridaemia: The involvement of insulin, insulin precursor species and insulin resistance
80. Improvement of high-density lipoprotein-cholesterol levels: Ambulatory type I diabetics treated with the subcutaneous insulin pump
81. Plasma HDL-cholesterol and postheparin plasma hepatic endothelial lipase (HL) activity: Relationship to obesity and non-insulin dependent diabetes (NIDDM)
82. High-density lipoprotein composition in insulin-dependent diabetes mellitus
83. High density lipoprotein (HDL) metabolism in noninsulin-dependent diabetes mellitus: Measurement of HDL turnover using tritiated HDL
84. Independent regulation of plasma apolipoprotein CII and CIII concentrations in very low density and high density lipoproteins: Implications for the regulation of the catabolism of these lipoproteins
85. High density lipoportein metabolism
86. Increased apo A-I and apo A-II fractional catabolic rate in patients with low high density lipoprotein-cholesterol levels with or without hypertriglyceridemia
87. Low density lipoprotein metabolism in non-insulin-dependent diabetes mellitus
88. Lipoprotein metabolism in diabetes mellitus
89. Appearance of multidisperese low density lipoprotein and altered lipoprotein composition in non-insulin-dependent diabetes with type IIa hyperlipoproteinemia
90. LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetes
91. Insulin resistance and hyperinsulinemia in individuals with small, dense, low density lipoprotein particles
92. LDL subclass phenotypes and the risk factors of the insulin resistance syndrome
93. Prospective study of small LDLs as a risk factor for non-insulin dependent diabetes mellitus in elderly men and women
94. Low density lipoprotein subclass patterns and risk of myocardial infarction
95. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk
96. Epidemiology of triglycerides, small dense low-density lipoprotein, and lipoprotein (a) as risk factors for coronary heart disease
97. Suspectibility of small, dense, low-density, lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B
98. Identification of multiple dense LDL subfractions with enhanced susceptibility to in vitro oxidation among hypertriglyceridemic subjects. Normalization after clofibrate treatment
99. Low density lipoprotein receptor activity in cultured human skin fibroblasts: Mechanism of insulin-induced stimulation
100. SREBP-1 mediates activation of the low density lipoprotein receptor promoter by insulin and insulin-like growth factor-I
101. Hormonal regulation of the hepatic low density lipoprotein receptor and the catabolism of low density lipoproteins: Relationship with the secretion of very low density lipoproteins
102. Regulation of the production and catabolism of plasma low density lipoproteins in hypertriglyceridemic subjects. Effect of weight loss
103. Atherogenesis in diabetes
104. Augmentation of synthesis of plasminogen activator inhibitor type 1 by insulin and insulin-like growth factor type I: Implications for vascular disease in hyperinsulinemic states
105. Attenuated fibrinolysis and accelerated atherogenesis in type II diabetic patients
106. Effects of native, triglyceride-enriched, and oxidatively modified LDL on plasminogen activator inhibitor-1 expression in human endothelial cells
107. Very-low-density lipoprotein response element in the promoter region of the human plasminogen activator inhibitor-1 gene implicated in the impaired fibrinolysis of hypertriglyceridemia
108. Plasminogen activator inhibitor-1 activity is independently related to both insulin sensitivity and serum triglycerides in 70-year-old men
109. Induction of hyperinsulinemia combined with hyperglycemia and hypertriglyceridemia increases plasminogen activator inhibitor 1 in blood in normal human subjects
110. Insulin resistance and thrombosis: A cardiologist's view